What is AnaptysBio, Inc.'s G&A?

AnaptysBio, Inc. (ANAB) reported G&A of $26.2M in Q1 2026.

How has AnaptysBio, Inc.'s G&A changed year-over-year?

AnaptysBio, Inc.'s G&A increased by 85.4% year-over-year, from $14.13M to $26.2M.

What is the long-term trend for AnaptysBio, Inc.'s G&A?

Over 4 years (2021 to 2025), AnaptysBio, Inc.'s G&A has grown at a 24.0% compound annual growth rate (CAGR), from $21.49M to $50.74M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

AnaptysBio, Inc. ANAB G&A

G&A at other companies

Dianthus TherapeuticsDNTH

$12.47M+69.9%

Apogee Therapeutics, Inc.APGE

$21.95M+31.4%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Nektar TherapeuticsNKTR

$13.44M-44.8%

Segments

By segment

See full

Biopharma Company$18.86M—

Royalty Management Company$7.35M—

By product

See full

Internal Expenses$14.08M+63.9%

External Expenses$12.12M+119%

Other financials

Income statement

See full

Revenue$25.6M-8.0%

Operating income-$34.6M-25.8%

Net income-$52.9M-34.5%

EPS (diluted)-$1.84-43.8%

Balance sheet

See full

Cash & equivalents$248.5M+152%

Total debt$13.6K-99.9%

Total equity$12.7M-62.5%

Total assets$329.7M-21.9%

Cash flow

See full

Operating cash flow-$25.9M-142%

CapEx$17.0K-51.4%

Free cash flow-$25.9M-142%

Valuation

See full

Market cap$1.73B+180%

Enterprise value$1.48B+176%

P/S7.4×+1.9×

Profitability

See full

Operating margin17.6%+9.6pp

Net margin-49.9%-22.6pp

FCF margin1.9%+1.0pp

Returns & leverage

See full

Return on equity-343.8%-1,012pp

Debt / equity0×-0.5×

Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AnaptysBio, Inc.'s G&A?: AnaptysBio, Inc. (ANAB) reported G&A of $26.2M in Q1 2026.
How has AnaptysBio, Inc.'s G&A changed year-over-year?: AnaptysBio, Inc.'s G&A increased by 85.4% year-over-year, from $14.13M to $26.2M.
What is the long-term trend for AnaptysBio, Inc.'s G&A?: Over 4 years (2021 to 2025), AnaptysBio, Inc.'s G&A has grown at a 24.0% compound annual growth rate (CAGR), from $21.49M to $50.74M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.